ArticleAmerican journal of translational research2015
Anti-inflammatory and anti-apoptotic effects of oxysophoridine on lipopolysaccharide-induced acute lung injury in mice.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 12 citations in OpenAlex.
- Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.Frontiers in pharmacology · 2020Article
- Smoking Attenuates Efficacy of Penehyclidine Hydrochloride in Acute Respiratory Distress Syndrome Induced by Lipopolysaccharide in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells.Journal of cellular and molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxysophoridine (OSR) is an alkaloid with multiple pharmacological activities. This study aimed to investigate the protective effects and underlying mechanisms of OSR on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. Here, we found that OSR treatment markedly mitigated LPS-induced body weight loss and significant lung injury characterized by the deterioration of histopathology, histologic scores, wet-to-dry ratio, exduate volume, and protein leakage. OSR dramatically attenuated LPS-induced lung inflammation, as evidenced by the reduced levels of total cells, neutrophils, lymphocytes, and macrophages and pro-inflammatory cytokines (i.e., tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and monocyte chemoattractant protein-1) in bronchoalveolar lavage fluid and of their mRNA expression in lung tissues. OSR also inhibited LPS-induced expression and activation of nuclear factor-κB p65 in pulmonary tissue. Additionally, OSR administration markedly prevented LPS-induced pulmonary cell apoptosis in mice, as reflected by the decrease in expression of procaspase-8, procaspase-3, cleaved caspase-8, and cleaved caspase-3, and Bcl-2-associated X/B-cell lymphoma 2 ratio. These results indicate that OSR is a potential therapeutic drug for treating LPS-induced ALI.
Indexed as
Identifiers
26885265PMC4731665W2417256810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.